While current prediction markets focus on consumer topics like politics and sports, Katie Haun believes the larger, untapped opportunity lies in enterprise applications. Businesses can use these markets for sophisticated risk hedging, predicting outcomes of drug trials, or forecasting litigation results, creating a new category of institutional financial tools.

Prediction markets are not just for betting. They are becoming a valuable source of predictive data for enterprises, as shown by new partnerships with media giants like CNN and CNBC. This dual-purpose model, functioning as both a consumer product and a B2B data service, creates two distinct revenue streams.

New platforms frame betting on future events as sophisticated 'trading,' akin to stock markets. This rebranding as 'prediction markets' helps them bypass traditional gambling regulations and attract users who might otherwise shun betting, positioning it as an intellectual or financial activity rather than a game of chance.

It's a fool's errand to predict specific trial results. A robust quantitative approach to biotech focuses on underlying drivers and base rates. It positions a portfolio so the random, unpredictable nature of trial events plays out favorably over time, guided by factors like valuation and specialist ownership.

Experts express skepticism about the scientific value of AI-powered clinical trial prediction markets. The primary concern is that they function more as sophisticated betting platforms than tools to advance medicine. Their predictive power may not surpass the collective intelligence already embedded in public stock prices.

The true value of prediction markets lies beyond speculation. By requiring "skin in the game," they aggregate the wisdom of crowds into a reliable forecasting tool, creating a source of truth that is more accurate than traditional polling. The trading is the work that produces the information.

Bioethicist Jonathan Kimmelman argues that if prediction markets become highly effective, they destroy the ethical foundation of randomized trials. The principle of "equipoise" requires genuine uncertainty; if a market "knows" a drug is inferior, it becomes unethical to randomize patients to that treatment arm.

Prediction markets focused on specific outcomes, like the success of pharmaceutical clinical trials, can provide more accurate forecasts than individual experts. By incentivizing informed participants to bet, platforms like Endpoint Arena aggregate collective intelligence into a powerful signal for investors.

Unlike a focused prediction market, a company's stock price is a crude tool for forecasting a trial's success. The stock reflects many variables like capital reserves and supply chain risks, not just the scientific merit of one drug, making it a noisy signal for a specific clinical outcome.